Evidence map›Paper›PMID 36752778›Full record

ArticleMicrobial genomics2023

Ceftazidime-avibactam resistance in

Gabriele Arcari, Riccardo Polani, Francesco Bruno, Valerio Capitani, Federica Sacco, Gaia Menichincheri, Giammarco Raponi, Alessandra Carattoli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbial genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Dynamics of clinicalApplied and environmental microbiology · 2026
    Article
  3. Carriage of hypervirulent and ESBL-producingApplied and environmental microbiology · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gabriele ArcariDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Riccardo PolaniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Francesco BrunoDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Valerio CapitaniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Federica SaccoDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Gaia MenichincheriDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Giammarco RaponiDepartment of Public Health, Sapienza University of Rome, Rome, Italy.
Alessandra CarattoliDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Laboratory affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Italy.
Sapienza University of Rome · ITIstituto Pasteur · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The first reports of carbapenem-resistant

Indexed as

Anti-Bacterial AgentsKlebsiella pneumoniaeAzabicyclo Compoundsbeta-LactamasesCeftazidimeDrug CombinationsHumansAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo Compoundsbeta-LactamasesCeftazidimeDrug CombinationsendemicityKPCpKpQILST37

Identifiers

PMID36752778
PMCPMC9997735
OpenAlexW4319460890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.